Targeted treatment with EGFR TKIs: Front line options

preview_player
Показать описание

In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Charu Aggarwal discusses frontline options for targeted therapy with EGFR TKIs.

© 2018 Imedex, an HMP Company
  1. HMP Education
  2. Imedex
  3. CME
  4. Continuing Medical Education
  5. Education
  6. Accreditation
Рекомендации по теме
Targeted treatment with 0:20:24

Targeted treatment with EGFR TKIs: Front line options

Dermatologic Side Effects 0:10:04

Dermatologic Side Effects of EGFR-TKIs - 2022 Program: Targeted Therapies Forum

EGFR-TKI Therapy in 0:03:12

EGFR-TKI Therapy in Advanced NSCLC

2023 Best of 0:30:32

2023 Best of Lung: Targeted Therapies in Lung Cancer

EGFR TKIs and 0:05:22

EGFR TKIs and Their Side Effects - 2022 Program: Targeted Therapies Forum

EGFR TKIs Excite 0:01:24

EGFR TKIs Excite Treatment Landscape of EGFR-Mutant Lung Cancers

New target for 0:02:20

New target for treatment resistance after EGFR inhibitors found in lung cancer study

EGFR TKIs: Efficacy, 0:07:36

EGFR TKIs: Efficacy, Combinations, & Use After Chemotherapy - 2022 Program: Targeted Therapies F...

Additional EGFR-TKI Therapy 0:02:26

Additional EGFR-TKI Therapy Research in NSCLC

Advancements of Targeted 0:03:14

Advancements of Targeted Therapy for EGFR Mutations in NSCLC

Selecting EGFR Tyrosine 0:00:52

Selecting EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Lung Cancer

Treating Patients With 0:00:50

Treating Patients With EGFR-Mutant Lung Cancer With Targeted Therapies

Mechanisms of Resistance 0:21:09

Mechanisms of Resistance to EGFR TKI and New Treatment Strategies

Side Effects of 0:02:42

Side Effects of EGFR-TKIs: Pneumonitis and Cardiotoxicity - 2022 Program: Targeted Therapies Forum

JIN-A02: a highly 0:02:15

JIN-A02: a highly effective 4th generation EGFR-TKI, targeting EGFR C797S triple mutation in NSCLC

Neoadjuvant EGFR TKI 0:01:33

Neoadjuvant EGFR TKI trials in NSCLC

Addressing Key Targets 0:58:27

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies

Exploring neoadjuvant EGFR-TKIs 0:01:18

Exploring neoadjuvant EGFR-TKIs in lung cancer

EGFR TKIs as 0:04:38

EGFR TKIs as Adjuvant Therapy in NSCLC

Locally advanced NSCLC: 0:25:26

Locally advanced NSCLC: Combination therapy with targeted and immunotherapy agents

EGFR TKIs for 0:05:47

EGFR TKIs for Upfront Treatment of NSCLC

EGFR-TKIs in First-Line 0:02:34

EGFR-TKIs in First-Line EGFR+ Metastatic NSCLC

Dr. Bazhenova on 0:01:42

Dr. Bazhenova on Sequential Use of Immunotherapy and EGFR TKIs in Lung Cancer

Front-line targeted therapy 0:17:55

Front-line targeted therapy for advanced EGFR-positive disease